Axsome Therapeutics is a US-based biopharmaceutical company focused on treating central nervous system disorders. Their product pipeline includes AXS-05, which is in phase III clinical trials for the treatment of Alzheimer's and depression, as well as phase II for smoking cessation. The company is also developing AXS-07 for migraine, AXS-12 for narcolepsy and AXS-14 for fibromyalgia, with a collaboration agreement with Duke University for smoking cessation.